Home / Leaderboard / Soleus Capital Management, L.P.
Soleus Capital Management, L.P.
Guy Levy · Hedge Fund · Long/Short Equity
Soleus Capital Management, L.P. is a healthcare-focused investment firm founded in 2018 by Guy Levy and headquartered in Greenwich, Connecticut. The firm specializes in fundamental, research-driven investing across the innovative areas of life sciences, including biotechnology, medical technology, diagnostics, and genomics. Soleus aims to generate superior risk-adjusted returns by targeting idiosyncratic, catalyst-driven opportunities in both public and private markets. Its investment scope spans the healthcare lifecycle, from developmental-stage companies to commercial enterprises. The firm is recognized for its deep sector expertise and its ability to identify high-potential innovations that address significant unmet medical needs.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +165.5% |
| YTD return | +7.2% |
| Sharpe ratio | 3.81 |
| Win rate | 45% |
| AUM | $1.9B |
| Inception | Oct 1, 2025 |
| Updated | Oct 2, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $1.9B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://soleuscapital.com |
Current Holdings
Updated on Oct 2, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| KRYS | Krystal Biotech Inc | 17.4% | +21.7% |
| TGTX | TG Therapeutics Inc | 9.0% | +37.8% |
| NVCR | Novocure Ltd | 8.5% | +4.2% |
| PODD | Insulet Corporation | 7.7% | -9.7% |
| INSP | Inspire Medical Systems Inc | 7.3% | +38.8% |
| CELC | Celcuity LLC | 7.2% | -19.3% |
| UTHR | United Therapeutics Corporation | 5.8% | -1.6% |
| BBNX | Beta Bionics, Inc. Common Stock | 5.1% | +50.7% |
| RIGL | Rigel Pharmaceuticals Inc | 4.8% | +10.7% |
| ANIP | ANI Pharmaceuticals Inc | 3.4% | -8.7% |
| VCEL | Vericel Corp Ord | 3.1% | +15.5% |
| GERN | Geron Corporation | 2.9% | -21.8% |
| PRAX | Praxis Precision Medicines Inc | 2.7% | +121.2% |
| PBLS | Parabilis Medicines, Inc. Common Stock | 2.4% | -19.1% |
| ALKS | Alkermes Plc | 2.3% | +20.1% |
| PGNY | Progyny Inc | 2.2% | +0.8% |
| NPCE | Neuropace Inc | 2.2% | -12.9% |
| ERAS | Erasca Inc | 2.1% | -18.4% |
| INDV | Indivior PLC Ordinary Shares | 2.1% | +3.0% |
| GMED | Globus Medical | 1.9% | +1.4% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Sep 28, 2026 | SELL | RIGL | 4.6% → 4.8% |
| Sep 28, 2026 | SELL | KRYS | 17.4% → 17.4% |
| Sep 28, 2026 | SELL | GERN | 3.1% → 2.9% |
| Sep 28, 2026 | BUY | NPCE | 2.2% → 2.2% |
| Sep 28, 2026 | SELL | TGTX | 8.6% → 9.0% |
Investment Style Analysis
Soleus Capital Management, L.P. is widely recognized for employing a Long/Short Equity strategy. As of Oct 2, 2026, the firm oversees approximately $1.9B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology and Medical Devices sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Sep 28, Soleus Capital Management, L.P. made a significant move by reducing the position in RIGL. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
Soleus Capital employs a fundamentals-driven investment philosophy centered on identifying and supporting innovation within the life sciences and healthcare sectors. The firm conducts rigorous, research-intensive due diligence that leverages deep scientific and clinical expertise to evaluate clinical data, regulatory pathways, and competitive dynamics. Soleus typically focuses on small-to-mid-cap companies and seeks to invest in businesses advancing novel therapies and technologies that improve patient outcomes. Their strategy is catalyst-driven, prioritizing idiosyncratic opportunities over broader market trends. By taking a long-term view and partnering with high-quality management teams, Soleus aims to provide value throughout a company’s lifecycle, from early development through commercialization.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Soleus Capital Management, L.P..
Similar Investment Style
Based on Long/Short Equity.
- Perceptive Advisors LLC — Joseph Edelman · 3M -7.5%
- Glenview Capital Management, LLC — Larry Robbins · 3M +2.3%
- Zweig-DiMenna Associates, Inc. — Joseph DiMenna · 3M +6.8%
- Redmile Group, LLC — Jeremy Green · 3M -16.4%
Frequently asked questions
How is the simulated portfolio for Soleus Capital Management, L.P. constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Soleus Capital Management, L.P.'s largest holding?
As of the latest filing, Soleus Capital Management, L.P.'s top position is Krystal Biotech Inc (KRYS), representing 17.4% of the portfolio. This reflects a high-conviction bet by the institution.
What is Soleus Capital Management, L.P.'s historical performance and risk profile?
Our simulation indicates a total return of +165.5% with a win rate of 45%. Notably, the portfolio maintains a Sharpe Ratio of 3.81, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does Soleus Capital Management, L.P. primarily invest in?
Soleus Capital Management, L.P. has a strong preference for the Biotechnology sector, which makes up 51.6% of their disclosed assets. The portfolio also has exposure to Medical Devices, indicating a specific thematic focus.
Is Soleus Capital Management, L.P.'s portfolio concentrated or diversified?
Soleus Capital Management, L.P. runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 34.9% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has Soleus Capital Management, L.P. performed in 2026?
Our AI-simulated model portfolio for Soleus Capital Management, L.P. tracks a Year-to-Date (YTD) return of +7.2%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Guy Levy manage Soleus Capital Management, L.P. directly?
Yes, Guy Levy serves as the key portfolio manager for Soleus Capital Management, L.P., overseeing the investment strategy and final capital allocation decisions.